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Background. Persistent carriers have a higher risk of Staphylococcus aureus infections than noncarriers but a
lower risk of bacteremia-related death. Here, the role played by anti-staphylococcal antibodies was studied.
Methods. Serum samples from 15 persistent carriers and 19 noncarriers were analyzed for immunoglobulin (Ig)
G, IgA, and IgM binding to 19 S. aureus antigens, by means of Luminex technology. Nasal secretions and serum
samples obtained after 6 months were also analyzed.
Results. Median serum IgG levels were significantly higher in persistent carriers than in noncarriers for toxic
shock syndrome toxin (TSST)–1 (median fluorescence intensity [MFI] value, 11,554 vs. 4291; P  .001) and staph-
ylococcal enterotoxin (SE) A (742 vs. 218; P  .05); median IgA levels were higher for TSST-1 (P  .01), SEA, and
clumping factor (Clf) A and B (P  .05). The in vitro neutralizing capacity of anti–TSST-1 antibodies was correlated
with theMFI value (R2  0.93) andwas higher in persistent carriers (90.6%vs. 70.6%;P  .05). Antibody levels were
stable over time and correlated with levels in nasal secretions (for IgG, R2  0.87; for IgA, R2  0.77).
Conclusions. Antibodies to TSST-1 have a neutralizing capacity, andmedian levels of antibodies to TSST-1, SEA,
ClfA, and ClfB are higher in persistent carriers than in noncarriers. These antibodies might be associated with the
differences in the risk and outcome of S. aureus infections between nasal carriers and noncarriers.
Staphylococcus aureus is an important pathogen that
causes superficial skin infections (furuncles and impe-
tigo) as well as invasive infections that result in ab-
scesses, endocarditis, and bacteremia [1]. Persistent car-
riers of S. aureus, comprising 20% of the healthy
population [2, 3], have an increased risk of developing
such infections [4–6], including a 3-fold higher risk of
acquiring S. aureus bacteremia. Surprisingly, the risk of
death in carriers with bacteremia is significantly lower
than that in noncarriers with bacteremia [5, 7]. An ex-
planation for this observation has not yet been provided,
although a role for the immune system has been pro-
posed. Genotyping has revealed that 80% of strains that
cause bacteremia in persistent carriers are endogenous
[5, 8]. Because of long-time exposure to their colonizing
strain, carriers may have developed antibodies that pro-
tect them from bacteremia-related death. Otherwise,
noncarriers may harbor antibodies that protect them
from nasal colonization [9], and they therefore remain
at lower risk of acquiring S. aureus bacteremia. Anti-
staphylolysin titers were found to be higher in carriers
than in noncarriers [10], but the 2 groups had similar
concentrations of antibodies to teichoic acid [11].
Recently, a higher level of IgG in noncarriers than in
carriers was reported for -hemolysin, major autolysin,
iron-responsive surface determinant (Isd) A and H, im-
munodominant secretory antigen A (IsaA), major his-
tocompatibility complex class II analogue protein w
(Map-w), and clumping factor (Clf) B [9, 12]. These
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latter studies focused mainly on antibodies to microbial sur-
face components recognizing adhesive matrix molecules
(MSCRAMMs), proteins that are generally considered im-
portant for host colonization [13, 14].
At present, little is known about the humoral immune re-
sponse to staphylococcal enterotoxins (SEs) and immune-
modulating proteins in persistent carriers and noncarriers. SEs
are superantigens and, therefore, potent proinflammatory
agents [15]. They have been implicated in the pathogenesis of
toxic shock [15, 16]. The immune modulators staphylococcal
complement inhibitor (SCIN) and extracellular fibrinogen-
binding protein (Efb) are potent complement inhibitors that
lead to diminished phagocytosis and killing by human neutro-
phils [17, 18]. Chemotaxis inhibitory protein of S. aureus
(CHIPS) impairs the response of neutrophils and monocytes to
formylated peptides and C5a [19]. Consequently, both the SEs
and the immune-modulating proteins might play a role in S.
aureus carriage and disease.
In the present study, we determined levels of antibodies to 9
MSCRAMMs, 7 SEs, and 3 immune-modulating proteins in se-
rum samples and nasal secretions from well-defined persistent
carriers and noncarriers and measured the stability of anti-
staphylococcal antibody levels over time.
METHODS
Serum samples, nasal secretions, and nasal swab samples. At the
beginningofthestudy,allvolunteerscompletedaquestionnaireonage,
sex,weight,height,nationality,occupation,smokinganddrinkinghab-
its, medication (including antibiotic usage), andmedical history. Cri-
teria for exclusion were diabetes mellitus, renal insufficiency, chronic
obstructive pulmonary disease, heart disease, immunocompromised
status, immunosuppressant use, antibiotic use in the last 4 weeks, and
skin diseases (such as impetigo and eczema). All 40 participants (me-
dian age, 36.9 years; age range, 21–60 years) fulfilled the inclusion cri-
teriaanddidnotsuffer fromapparent staphylococcal infectionsduring
thestudyperiod.Venousbloodsamplesandat least3consecutivenasal
swab samples (at 2-week intervals) were obtained for each of the 40
healthyvolunteers.After 6months, a secondblood sample and2addi-
tional nasal swab samples were collected from 11 of these volunteers.
Nasalswabsampleswereprocessedasdescribedelsewhere[2].Subjects
were classified as persistent carriers when all nasal swab cultures were
positive for S. aureus, as intermittent carriers when 1 or 2 nasal swab
cultureswere positive, and as noncarriers when all nasal swab cultures
werenegative.Nasal secretions from13volunteerswerecollectedat the
beginning of the study by vacuum-aided suction without chemical
stimulation and processed as described elsewhere [20, 21]. The col-
lected fluid was sonicated in a water bath to disrupt the mucoprotein
aggregates and facilitate reproducible handling. The secretions and se-
rum samples were stored at80°C until use. Human pooled serum
(HPS) from 36 healthy donors of unknown S. aureus nasal carriage
state was used as a standard during Luminex experiments. Volunteers
providedwritten informed consent, and the localmedical ethics com-
mittee of the ErasmusMedical Center Rotterdam approved the study
(MEC-2007-106).
Antigens. The MSCRAMMs ClfA and ClfB, S. aureus sur-
face protein (Sas) G, IsdA and IsdH, fibronectin-binding protein
A and B, and serine-aspartate dipeptide repeat proteins (Sdr) D
and E were expressed with a His tag in Escherichia coli XL1-blue
strain and purified under denaturing conditions with nickel–
nitrilotriacetic acid agarose (Qiagen) recognizing the His tag;
quality control was done using SDS-PAGE and mass spectrom-
etry (Ultraflex MALDI-TOF; Bruker Daltonics). Staphylococcal
enterotoxin (SE) A was purchased from Sigma. Recombinant
proteins SEB, SEI, SEM, SEO, SEQ, and toxic shock syndrome
toxin (TSST)–1 were provided by Dr. S. Holtfreter and D. Gru-
mann (University of Greifswald) [16]. Dr. S. Rooijakkers (Uni-
versity Medical Center Utrecht) provided the recombinant pro-
teins CHIPS and SCIN. Prof. J. I. Flock (Karolinska Institutet)
supplied the Efb [22–25].
Coupling methods. To quantify antibodies directed against
the 19 S. aureus proteins simultaneously, the recently introduced
microsphere (bead)–based flow cytometry technique (xMAP; Lu-
minex) was applied. The purified proteins were coupled to Sero-
MAP beads, a carboxylated bead type developed for serological ap-
plications. The coupling procedure was performed as described
elsewhere [26, 27]. In brief, 25 g of protein was added to
5.0  106 microspheres. This amount of protein was found to
be optimal. As an activation buffer, we used 100mmol/L mono-
basic sodium phosphate (pH 6.2). To activate the carboxyl
groups on the surface of the beads, 10 L of 50 mg/mL
N-hydroxysulfosuccinimide and 1-ethyl-3-(3-dimethylamino-
propyl) carbodiimide was used (Pierce Biotechnology). The
coupling buffer consisted of 50 mmol/L 2-(N-morpholino)-
ethanesulfonic acid (pH 5.0; Sigma-Aldrich). The final concen-
tration of microspheres was adjusted to 4000 beads/L with
blocking-storage buffer (PBS-BN; PBS, 1% bovine serum albu-
min, and 0.05% sodium azide [pH 7.4]). Themicrospheres were
protected from light and stored at 4°C until use. For control
beads, the coupling procedure was done in the absence of S.
aureus protein. In each experiment, control beads were included
to determine nonspecific binding. In case of nonspecific bind-
ing, the median fluorescence intensity (MFI) values were sub-
tracted from the antigen-specific results. As a negative control,
PBS-BN was included.
Multiplex S. aureus antibody assay. The multiplex assay
(serum incubatedwith the different fluorescence-colored antigen-
coupled beads mixed in 1 well) was validated by comparing the
MFI values for HPS obtained with this multiplex assay with the
results for HPS obtained with singleplex assays (serum incu-
bated with each different color of antigen-coupled beads in sep-
arate wells). After validation, the different antigen-coupled
microspheres were mixed to a working concentration of 4000
beads per color per well. The procedure was the same as de-
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scribed elsewhere [26]. Serum samples were diluted 1:100 in
PBS-BN for measurement of antigen-specific IgG and IgA and
1:25 for measurement of IgM. Fifty microliters per diluted sam-
ple was incubated with the microspheres in a 96-well filter mi-
crotiter plate (Millipore) for 35 min at room temperature on a
Thermomixer plate shaker (Eppendorf). The plate was washed
twice with assay buffer (PBS-BN) that was aspirated by vacuum
manifold. Themicrospheres were resuspended in 50L of assay
buffer. In separate wells, 50 L of a 1:200 dilution of R-
phycoerythrin (RPE)–conjugated AffiniPure goat anti–human
IgG and IgA and 50 L of a 1:50 dilution of RPE-conjugated
donkey anti–human IgM (Jackson Immuno Research) were
added. The plate was incubated for 35 min at room temperature
on the plate shaker and washed. The microspheres were resus-
pended in 100 L of assay buffer. Measurements were per-
formed on the Luminex 100 instrument (BMD) using Luminex
IS software (version 2.2). Tests were performed in triplicate, and
the MFI values, reflecting quantitative antibody levels, were av-
eraged. The coefficient of variation (CV) was calculated for each
serum sample and averaged per protein and antibody isotype.
For nasal secretions, the procedure was identical. Nasal secre-
tions were diluted 1:20, and RPE-conjugated goat anti–human
IgG and IgA were diluted 1:50.
TSST-1 neutralization assay. The in vitro TSST-1 neutral-
ization assay was performed as described elsewhere [16, 28]. Ini-
tially, the concentration of recombinant TSST-1 that elicited
submaximal T cell proliferation was determined (10 pg/mL).
Subsequently, 10 pg/mL TSST-1 was incubated with serial dilu-
tions (1:50 to 1:6250) of heat-inactivated serum from the 40
healthy volunteers. At higher serum dilutions, maximal inhibi-
tion could no longer be obtained. As a control, TSST-1 was in-
cubated with RPMI 1640 supplemented with 10% fetal bovine
serum. After 20 min, 1  105 peripheral blood mononuclear
cells from healthy blood donors were added to test for TSST-1
neutralizing antibodies. T cell proliferation was determined by
the incorporation of [3H]-thymidine after 72 h, quantified by
calculating the area under the proliferation curve, and expressed
as a percentage of the control without human serum. All mea-
surements were performed in triplicate and repeated in 2 inde-
pendent experiments.
Statistical analysis. The Mann-Whitney U test was used to
compare median differences in anti-staphylococcal antibody
levels and themedian neutralizing capacities of serum from per-
sistent carriers and noncarriers. To compare the antibody levels
in the first and second serum samples from an individual, paired
t tests were used. Correlations between antigen-specific IgG and
IgA in serum and nasal secretions were assessed using Pearson’s
correlation coefficient. Nonlinear regression was used to de-
scribe the relation betweenMFI value and neutralizing capacity.
Differences were considered statistically significant when 2-
sided P values were.05.
RESULTS
Control of the multiplex assay and reproducibility. First, the
multiplex assay was validated. TheMFI values obtained for HPS
with the multiplex assay were between 93% and 116% (median,
100%) of those obtained with the singleplex assays, so it was
valid to use the multiplex assay. Serum incubated with control
beads (beads without protein coupled on their surface) resulted
inmedianMFI values for IgG, IgA, and IgMof 14 (range, 6–82),
6 (range, 3–22), and 75 (range, 3–957), respectively. This indi-
cates that there was low nonspecific binding (with the exception
of IgM in 1 sample). The negative control (PBS-BN) incubated
with protein-coupled beads resulted in low MFI values (10).
Interassay variation was calculated fromMFI values obtained
from serum samples (n  40) run in 3 separate assays and was
averaged per protein and antibody isotype. For IgG, the median
CV was 15%, and the range was 5% (CHIPS) to 25% (SEO); for
IgA, the median CV was 20%, and the range was 7% (Efb) to
25% (SdrD, SEB, SEI, and SasG); and for IgM, the median CV
was 16% and the range was 7% (ClfA) to 43% (SEO; relatively
high CV due to MFI values close to 0). Earlier studies found
equal CVs for interassay variation [26, 29–31].
Differences in antigen-specific antibodies in serum from per-
sistent carriers and noncarriers. Nineteen volunteers were clas-
sified as noncarriers (48%), 6 as intermittent carriers (15%), and 15
as persistent carriers (38%). TheMFI valued reflecting serum anti-
body levels for eachpersonandantibody isotypeare showninfigure
1. For most of the antigens there was no apparent quantitative dif-
ference in antibody level between persistent carriers and noncarri-
ers. However, the median serum levels of IgG directed against
TSST-1andSEAwere significantlyhigher inpersistent carriers than
in noncarriers (MFI value, 11,554 vs. 4291 [P  .001] and 742 vs.
218 [P  .05], respectively). Additionally, the median IgA se-
rum level was significantly higher in persistent carriers than in
noncarriers for TSST-1 (973 vs. 155; P  .01), SEA (127 vs. 32;
P  .05), ClfA (1661 vs. 441; P  .05), and ClfB (792 vs. 356;
P  .05). The MFI values reflecting IgG levels were highest for
CHIPS, SCIN, and TSST-1; those for IgA were highest for
CHIPS, SCIN, and Efb; and those for IgM the were highest for
ClfA and SasG.
Stability of anti-staphylococcal antibody levels in serum. To
study the stability of the level of S. aureus antigen–specific antibod-
ies over time, a second serum sample and 2 more nasal swab sam-
pleswerecollectedafter6months from11volunteers.Noneof these
volunteers reported suffering from an apparent S. aureus infection
between these time points. One of the volunteers (volunteer 2) was
classified as an intermittent carrier instead of a noncarrier because
of a single positive nasal swab culture after 6months. For all volun-
teers, the levels of IgG and IgA to the 19 S. aureus proteins did not
change significantly during the 6-month period (P  .05). Figure
2 shows representative results for the stability of IgG levels for 4
S. aureus proteins.
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Correlation between anti-staphylococcal antibody levels in
serum and nasal secretion. To determine the correlation be-
tween anti-staphylococcal antibodies in serum and nasal secre-
tions, these samples were collected simultaneously from 13 vol-
unteers, and the mean IgG and IgA levels (reflected by MFI
values) in these samples were calculated for each protein. The
correlation coefficient for the comparison between serum and
nasal secretions was 0.87 for IgG and correlation 0.77 for IgA
(figure 3).
TSST-1 neutralization assay. The neutralizing capacity of
TSST-1–specific antibodies in the 40 human samples was deter-
mined. The median neutralizing capacity was significantly
higher in persistent carriers than in noncarriers (90.6% vs.
70.6%; P  .05) (figure 4A). The level of IgG binding to TSST-1
is highly related to the neutralizing capacity of the serum samples
(R2  0.93) (figure 4B).
DISCUSSION
We developed an S. aureusmultiplex immunoassay that enables
simultaneous quantification of antibodies to 19 antigens in small
serumvolumes. This assay is thereforemore informative and less
time- and serum-consuming than the conventional ELISA tech-
nique. Themethods was used to determine the levels of antigen-
specific IgG, IgA, and IgM in serum samples from persistent
carriers, intermittent carriers, and noncarriers of S. aureus. An
important message of our analyses is that anti-staphylococcal
antibody levels showed extensive interindividual variability (fig-
ure 1), probably owing to the variable number of previous en-
counters with different S. aureus strains of diverse antigenicity as
well as interindividual differences in the ability to mount an
antigen-specific humoral immune response. In the group of per-
sistent carriers, differences in carrier strain type (as determined
by pulsed-field gel electrophoresis [PFGE]; data not shown)
might also contribute to the diversity in antibody levels. Thirteen
different PFGE types were found; only 3 of 15 persistent carriers
carried the same strain.
The most striking difference between persistent carriers and
noncarriers was the median level of IgG to TSST-1 (P  .001).
An earlier study showed that individuals harboring TSST-1–
producing strains had significantly higher levels of serum anti-
body to TSST-1 than did individuals who carried strains without
TSST-1 or who did not carry S. aureus at all [32]. In our study, 5
(33%) of the 15 persistent carriers carried a TSST-1–positive
strain (as determined by polymerase chain reaction; data not
shown), which indicates that current carriage of a TSST-1–pos-
itive strain does not fully explain the higher antibody levels in
persistent carriers. It is likely that the number of previous en-
counters with such strains also plays a role. We have shown that
the level of anti–TSST-1 IgG is highly correlated with the neu-
tralizing capacity of these antibodies (R2  0.93) (figure 4B).
This implies that these anti–TSST-1 antibodies are functional. It
Figure 1. Median fluorescence intensity (MFI) values reflecting levels
of antigen-specific IgG, IgA, and IgM for 19 Staphylococcus aureus
antigens in 40 volunteers. Each symbol represents a single volunteer; red
triangles represent persistent carriers, green diamonds represent inter-
mittent carriers, and blue squares represent noncarriers. Horizontal lines
indicate median levels of anti-staphylococcal antibodies for persistent
carriers and noncarriers, and arrows indicate statistically significant
differences in median values (persistent carriers vs. noncarriers, Mann-
Whitney U test). For IgG, differences were significant for toxic shock
syndrome toxin (TSST)–1 (11,554 vs. 4291; P  .001) and staphylococcal
enterotoxin (SE) A (742 vs. 218; P  .05); for IgA, differences were
significant for TSST-1 (973 vs. 155; P  .01), SEA (127 vs. 32; P  .05),
and clumping factor (Clf) A and B (for ClfA, 1661 vs. 441; for ClfB, 792 vs.
356; P  .05). CHIPS, chemotaxis inhibitory protein of S. aureus; Efb,
extracellular fibrinogen-binding protein; Fnbp, fibronectin-binding protein;
Isd, iron-responsive surface determinants; Sas, S. aureus surface protein;
SCIN, staphylococcal complement inhibitor; Sdr, serine-aspartate dipep-
tide repeat protein.
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is known that humans with high anti–TSST-1 antibody levels do
not develop toxic shock syndrome when they become infected
with a TSST-1–expressing S. aureus strain [33]. As stated else-
where, it is also known that carriers have a 3-fold higher risk of
acquiring S. aureus bacteremia than do noncarriers but a signif-
icantly lower risk of S. aureus bacteremia–related death [5].
Therefore, a possible explanation for this observation is that per-
sistent carriers are protected from toxic shock syndrome because
they have a high level of TSST-1–neutralizing antibodies and,
consequently, a lower risk of death than noncarriers. These ob-
servations should be verified by studying persistent carriers and
noncarriers with bacteremia; their anti–TSST-1 antibody levels
should be determined and correlated with the outcomes of in-
fection (work in progress).
Other significant differences between persistent carriers and
noncarriers were found for IgG directed against SEA (P  .05)
and IgA directed against TSST-1 (P  .01), SEA, ClfA, or ClfB
(P  .05). These levels were found to be higher in persistent
carriers than in noncarriers. Two other studies focusing on anti-
staphylococcal antibodies showed higher IgG levels for major
autolysin, ClfB, IsdA, IsdH, IsaA, Map-w, and -hemolysin in
noncarriers than in persistent carriers [9, 12]. Although these
authors did not measure anti-enterotoxin antibodies or anti-
bodies to immune-modulating proteins, the differences found
between persistent carriers and noncarriers differed from our
data. One possible explanation for this apparent discrepancy is
that the carrier state was less well defined in these studies. Dryla
et al. [12] defined persistent carriers and noncarriers as individ-
uals who tested culture positive or negative at least twice, but
they did not report whether the carrier state was based on nasal
or pharyngeal swab samples (or both) or at what intervals these
swab samples were collected. Clarke et al. [9] defined carriers
and noncarriers as individuals who were culture positive or neg-
ative for S. aureus on the basis of just a single nasal swab sample,
which cannot reliably distinguish between the different carrier
states. Thus, the differences in anti-staphylococcal antibody lev-
els observed in these studies might be explained by the fact that
carriage was not defined according to a precise and validated
“culture rule,” which is based on 2 nasal swab samples and quan-
titative culture data [2]. In the present study, we used at least 3
nasal swab samples collected at 2-week intervals to define the
carrier state.
Figure 2. Stability of IgG levels, reflected by median fluorescence intensity (MFI) values for Staphylococcus aureus proteins in serum samples from
11 healthy volunteers (1–11) at 0 and 6 months (t  0 and t  6). Error bars represent SEs. CHIPS, chemotaxis inhibitory protein of S. aureus; Clf,
clumping factor; Isd, iron-responsive surface determinant; TSST, toxic shock syndrome toxin.
Figure 3. Correlation between IgG and IgA levels in serum and nasal
secretions. Mean IgG and IgA levels in serum and nasal secretions,
reflected by median fluorescence intensity values, were calculated for
each protein. Pearson’s correlation coefficient was used. CHIPS, chemo-
taxis inhibitory protein of S. aureus; Clf, clumping factor; Efb, extracel-
lular fibrinogen-binding protein; Isd, iron-responsive surface determinant;
SCIN, staphylococcal complement inhibitor; TSST, toxic shock syndrome
toxin.
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The observed IgG and IgAMFI values were highest for CHIPS
and SCIN, indicating that these staphylococcal proteins are quite
immunogenic. The IgM values were highest for SasG, ClfA, and
IsdA. This can be due to a primary immune response to recent
exposure to these antigens or to so-called natural IgM antibodies
that appear in the absence of stimulation by specific antigens and
that are secreted by long-lived, self-renewing B cells belonging to
the B1 subset [34]. These natural antibodies are commonly
polyspecific and play an important role in the antimicrobial re-
sponse in humans [35]. Even though themeasured IgMantibod-
ies may not be antigen specific, they were directed mostly to
MSCRAMMs. This implies thatMSCRAMMs are structures that
are recognized in an early phase by the immune system and that
natural IgM antibodies recognize antigens in a very economic
way [34]. Antigen-specific IgG and IgA levels for all volunteers
and to all 19 antigens were stable over a period of 6 months.
Another study also showed antibody levels to 4 S. aureusproteins
(IsdH,Map-w, SA0688, and SA2505) remaining stable over time
[36]. Stability is the result of humoral memory. Humoral mem-
ory is assumed to rely on long-lived plasma cells, which even
without antigenic contact will secrete antibodies for many years,
and memory B cells, which can be (re)activated by antigen
and/or polyclonal stimuli [37].
Components of nasal secretions that complement the innate
host defense include IgG and IgA [21, 38]. Therefore, antigen-
specific IgG and IgA levels in nasal secretions were determined.
IgG and IgA values were highest for CHIPS. Anti-staphylococcal
antibody levels in nasal secretions correlated with levels in se-
rum, although for antigen-specific IgA in serum and nasal secre-
tions the correlation was somewhat lower (R2  0.77) than that
for IgG (R2  0.87) (figure 3). There might be an explanation
for this observation. In blood, IgA is found predominantly as a
monomer, and the ratio of IgA1 to IgA2 is 4:1. In mucosal
secretions, IgA is produced almost exclusively as a dimer, and the
ratio of IgA1 to IgA2 is 3:2 [39, 40]. Therefore, although IgG
simply diffuses from the vascular department into the tissues
and similarly distributed antigen-specific IgG molecules are
measured in blood and nasal secretions, for IgA this is not the
case.
In the present study, we focused on nasal carriage. In the ab-
sence of nasal carriage, the likelihood of being a throat carrier is
12.6% [41]; a rectal carrier, 3.2% [42, 43]; and an axilla carrier,
2% [44]. In our study, this would mean that only a few of the
intermittent and noncarriers would be reclassified into different
S. aureus carriage types, which would not affect the results sig-
nificantly. However, it does show the importance of reporting
the culture sites when defining the S. aureus carriage state.
Although our study was focused exclusively on antibodies di-
rected against S. aureus proteins, it should be noted that cell-wall
components (such as capsular polysaccharide 5 and 8 [45], pep-
tidoglycan [46] and lipoteichoic acid [47]) are also immuno-
genic. Therefore, including these cell-wall components in future
studies is important; this is the topic of our currentmethodolog-
ical investigations.
We have developed a novel high-throughput, low-volume
method for detecting levels of antibodies to a wide range of
staphylococcal proteins. We showed that anti-staphylococcal
antibody levels in serum are highly variable, are stable over time,
and correlate well with antibody levels in nasal secretions. Anti-
bodies to TSST-1 have a neutralizing capacity, andmedian levels
of antibodies to TSST-1, SEA, ClfA, and ClfB are higher in per-
sistent carriers than in noncarriers. These antibodies might be
associated with the risk of developing S. aureus infections and
might be responsible for the lower risk of mortality observed in
S. aureus carriers with bacteremia than in S. aureus noncarriers
with bacteremia [5].
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